OneSource Specialty Pharma has achieved a significant regulatory milestone with its flagship manufacturing unit in Bengaluru receiving Good Manufacturing Practices (GMP) certification from ANVISA, Brazil’s premier health authority. The approval follows a successful inspection conducted in November 2024 and positions the company to expand into one of the world’s largest pharmaceutical markets. This development is especially timely as Brazil prepares to welcome generic versions of Semaglutide, a blockbuster drug category. The move reinforces OneSource’s standing as a high-quality contract development and manufacturing organization (CDMO) for biologics and drug-device combinations.
Regulatory Clearance: A Strategic Breakthrough
<strong>OneSource Specialty Pharma’s Unit 2 in Bengaluru—its flagship manufacturing facility—has now earned full compliance certification under ANVISA’s Good Manufacturing Practices (GMP) standards. The certification, awarded following a detailed regulatory audit in November 2024, validates the plant’s capability to produce pharmaceuticals in line with the highest international quality standards. This endorsement not only affirms OneSource’s robust compliance infrastructure but also enables it to commence exports of critical biologics and injectable formulations, including drug-device combinations (DDCs), to Brazil. Such certification is a prerequisite for foreign suppliers intending to tap into Brazil’s tightly regulated pharmaceutical sector.
Brazil: A Lucrative and Timely Market Opportunity
Brazil is emerging as a key global market for specialty pharmaceuticals, especially with its increasing healthcare expenditure and regulatory openness to generics. Of particular note is the upcoming market opportunity for generic Semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist that is revolutionizing the treatment of Type 2 diabetes and obesity. With the certification now in hand, OneSource is strategically positioned to capitalize on Brazil’s 2026 entry into the generic Semaglutide space. This adds a substantial revenue channel for the company and enhances its value proposition to partners seeking rapid market access in Latin America.
Manufacturing Capabilities: Biologics and Beyond
Unit 2 is purpose-built for the production of high-value biologic drug substances and finished products, including:
- Injectable formulations
- Drug-device combinations (DDCs)
- Biosimilars and complex molecules
This facility plays a pivotal role in OneSource's integrated CDMO services, offering end-to-end solutions from formulation to commercial-scale production. The recent GMP nod further fortifies its credibility among multinational partners.
Leadership Perspective: Confidence in Execution
Neeraj Sharma, CEO and Managing Director of OneSource, emphasized the significance of this milestone: “This approval enables us to supply advanced pharmaceutical products—including GLP-1-based drug-device combinations—into the Brazilian market upon product-specific approvals by our partners. It’s a critical step forward, especially as Brazil gears up for the introduction of generic Semaglutide in 2026.”
Sharma also highlighted the strategic foresight involved in targeting Brazil—a market with expanding demand for high-quality generics, stringent compliance norms, and a sizable patient population.
Company Background: From Stelis Biopharma to OneSource
Formerly known as Stelis Biopharma Ltd, OneSource Specialty Pharma has undergone a strategic rebranding to reflect its core focus on specialty pharma CDMO services. The company is fast becoming a global contender in contract manufacturing for niche and high-barrier pharmaceutical products, supported by a robust regulatory track record and state-of-the-art facilities.
Stock Market Outlook and Investor Confidence
While the company is privately held, such regulatory wins often signal strong forward momentum and enhanced valuation in future fundraising or public listing scenarios. If OneSource chooses to go public or seek institutional investment, this GMP certification will serve as a strong validator of its operational maturity and global aspirations.
Conclusion
With ANVISA’s GMP certification now secured, OneSource Specialty Pharma is poised to become a significant player in the Latin American pharmaceutical supply chain. By targeting a high-growth therapeutic segment like Semaglutide and reinforcing its commitment to compliance and quality, the company is aligning itself for scalable success. This development marks not just a regulatory win but a strategic inflection point in its global expansion journey.
Comments